FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: NASDAQ:ORCL

Sort
E.g., 2013-05-19
E.g., 2013-05-19
Enter a comma separated list of user names.

Fulsome Volume Stock at NASDAQ - ORCL

Posted by akki on December 22nd, 2011

Oracle Corporation (NASDAQ:ORCL) incorporated in 2005, is an enterprise software company. The Company develops, manufactures, markets, distributes and services database and middleware software, applications software and hardware systems, consisting primarily of computer server and storage products.

ORCL, Oracle Corporation

** On its first quarter fiscal 2012, ORCL reported that its GAAP total revenues increased 12% to $8.4 billion with GAAP earnings per share of $0.36, up 34% year over year.

ORCL is the world's most complete, open, and integrated business software and hardware systems company.

More about ORCL at www.oracle.com

**********************

Cleantech Transit Inc. (CLNO)

Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company's ability to earn in 25% of the 500KW Merced Project.

Power3 Medical Products, Inc. (PWRM.OB) is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease).

Oracle Corp. (NASDAQ:ORCL) previously agreed to acquire Art Technology Group, Inc., a leading provider of eCommerce software and related on demand commerce optimization applications, through a cash merger for $6.00 per share, or approximately $1.0 billion.

Oracle Corp. (NASDAQ:ORCL) Chief Executive Officer Larry Ellison stated his company plans to produce evidence showing Hewlett-Packard Co. Chief Executive Officer Leo Apotheker was involved in an espionage effort centered on the theft of Oracle software. Ellison said if Apotheker stays away from HP, Oracle can’t subpoena him to testify at a trial that starts next week.

Pages

ADVERTISE WITH US